Dáil Éireann Debate, Wednesday - 17 January 2024
1592. Deputy Bríd Smith asked the Minister for Health the number of ministerial licence applications and MCAP applications have been made by clinics (details supplied); what products are available from these clinics; which products are available under MCAP and covered for reimbursement; when the MCAP review report is expected; and if he will make a statement on the matter. [57098/23]
View answerThe identity of clinicians who either apply for a Ministerial Licence or to enter the Cannabis for Medical Use Register for the purpose of treating their patients is confidential and will not be made public.
The products available to MCAP patients are defined as "specified controlled drugs" S.I. No. 262/2019 - Misuse Of Drugs (Prescription And Control Of Supply Of Cannabis For Medical Use) Regulations 2019, and are contained in Schedule 1 of the Regulations as set out below and are covered by the Long |Term Illness, GMS or Medical Card as appropriate.
|
Name of Cannabis product or preparation and brand name |
Dosage form |
Concentration of THC (percentage, weight/weight or weight/volume) |
Name of manufacturer |
|
Aurora High CBD Oil Drops |
Oral solution |
Less than 3% w/v (< 30mg/ml) This product also contains cannabidiol (CBD) 60% w/v (600mg/ml) |
Aurora Cannabis Enterprises Inc., 4439 Township Road 304, Cremona, Alberta, Canada, T0M 0R0 |
|
CannEpil ™ |
Oral solution |
0.5% w/v (5mg/ml) This product also contains cannabidiol (CBD) 10% w/v (100mg/ml) |
MGC Pharmaceuticals d.o.o., Kamniška ulica 29, 1000, Ljubljana, Slovenia |
|
Tilray Oral Solution THC10:CBD10 (25ml) |
Oral solution |
1% w/v (10mg/ml) This product also contains cannabidiol (CBD) 1% w/v (10mg/ml) |
Tilray Portugal Unipessoal Lda., Zona Industrial de Cantanhede, Lote 121, Cantanhede, 3060-197, Portugal |
|
Aurora Sedamen Softgels |
Capsules |
5mg/capsule This product also contains cannabidiol (CBD) less than 0.2mg/capsule |
Aurora Cannabis Enterprises Inc. 4250 14th Avenue, Markham, Ontario, Canada L3R 0J3 |
|
Oleo Bedrobinol |
Dried flower |
13.5% w/w (135mg/g) This product also contains cannabidiol (CBD) less than 1.0% w/w (less than 10mg/g) |
Bureau voor Medicinale Cannabis Postbus 16114 2500 BC DEN HAAG The Netherlands |
|
Oleo Bedrocan |
Dried flower |
22% w/w (220mg/g) This product also contains cannabidiol (CBD) less than 1.0% w/w (less than 10mg/g) |
Bureau voor Medicinale Cannabis Postbus 16114 2500 BC DEN HAAG The Netherlands |
|
Althea CBD12:THC10 (50ml) |
Oil |
1% w/v THC (10mg/ml) This product also contains 1.25% w/v (12.5mg/ml) cannabidiol (CBD) |
Tasmanian Alkaloids pty Ltd T/A Extractas Bioscience, Westbury, Tasmania, Australia 7303 |
|
Oleo Genetics 10:10 |
Oil (oral solution) |
1% w/v (10mg/ml) This product also contains cannabidiol (CBD) 1% w/v (10mg/ml) |
ADREX Pharma GmbH Firmungstrabe 4 56068 Koblenz Germany |
|
Oleo Genetics 25:1 |
Oil (oral solution) |
2.5% w/v (25mg/ml) This product also contains cannabidiol (CBD) <0.1% w/v (<1mg/ml) |
ADREX Pharma GmbH Firmungstrabe 4 56068 Koblenz Germany |
|
Althea THC20:CBD1 (50ml) |
Oil |
2% w/v THC (20mg/ml) This product also contains <0.1% w/v (<0.1mg/ml) cannabidiol (CBD) |
Tasmanian Alkaloids pty Ltd T/A Extractas Bioscience, Westbury, Tasmania, Australia 7303 |
The MCAP review is anticipated to be completed in 2024.
